Mackenzie Financial Corp Invests $77,000 in Bioventus Inc. (NYSE:BVS)

Mackenzie Financial Corp purchased a new position in Bioventus Inc. (NYSE:BVS) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 13,335 shares of the company’s stock, valued at approximately $77,000.

Other hedge funds have also recently made changes to their positions in the company. Rhumbline Advisers boosted its position in shares of Bioventus by 5,367.9% in the 2nd quarter. Rhumbline Advisers now owns 52,437 shares of the company’s stock worth $302,000 after purchasing an additional 51,478 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Bioventus in the 2nd quarter worth approximately $647,000. LSV Asset Management purchased a new position in Bioventus in the 1st quarter worth approximately $1,170,000. Lazard Asset Management LLC purchased a new position in Bioventus in the 1st quarter worth approximately $40,000. Finally, Quadrature Capital Ltd purchased a new position in Bioventus in the 4th quarter worth approximately $85,000. 62.94% of the stock is owned by institutional investors.

Bioventus Price Performance

Shares of BVS opened at $11.59 on Wednesday. The firm has a market cap of $917.53 million, a PE ratio of -33.23 and a beta of 0.90. The company has a current ratio of 1.33, a quick ratio of 0.96 and a debt-to-equity ratio of 1.82. The firm has a fifty day simple moving average of $9.74 and a two-hundred day simple moving average of $7.16. Bioventus Inc. has a 1-year low of $2.85 and a 1-year high of $12.41.

Bioventus (NYSE:BVS) last announced its earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.12. The business had revenue of $151.22 million during the quarter, compared to analyst estimates of $137.70 million. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. During the same period in the previous year, the business earned $0.14 EPS. On average, equities analysts anticipate that Bioventus Inc. will post 0.4 EPS for the current year.

Wall Street Analysts Forecast Growth

BVS has been the subject of a number of recent analyst reports. Craig Hallum boosted their price objective on shares of Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, September 27th. Canaccord Genuity Group boosted their price objective on shares of Bioventus from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th.

Insider Buying and Selling at Bioventus

In related news, Director John A. Bartholdson acquired 80,000 shares of Bioventus stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $8.55 per share, for a total transaction of $684,000.00. Following the purchase, the director now directly owns 6,913,857 shares of the company’s stock, valued at approximately $59,113,477.35. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director John A. Bartholdson acquired 80,000 shares of Bioventus stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $8.55 per share, for a total transaction of $684,000.00. Following the purchase, the director now directly owns 6,913,857 shares of the company’s stock, valued at approximately $59,113,477.35. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director John A. Bartholdson acquired 25,500 shares of Bioventus stock in a transaction dated Monday, August 19th. The stock was bought at an average price of $8.55 per share, with a total value of $218,025.00. Following the completion of the purchase, the director now directly owns 6,939,357 shares in the company, valued at $59,331,502.35. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 32.90% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.